Boundless Bio Inc BOLD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BOLD is a good fit for your portfolio.
News
-
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
-
Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
-
Boundless Bio Announces Pricing of Initial Public Offering
Trading Information
- Previous Close Price
- $11.30
- Day Range
- $9.94–11.50
- 52-Week Range
- $9.94–15.24
- Bid/Ask
- $10.04 / $11.25
- Market Cap
- $224.39 Mil
- Volume/Avg
- 160,267 / 335,992
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 72
- Website
- https://www.boundlessbio.com
Valuation
|
Metric
|
BOLD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BOLD
|
|---|---|
Quick Ratio | 12.90 |
Current Ratio | 13.27 |
Interest Coverage | — |
Quick Ratio
BOLD
Profitability
|
Metric
|
BOLD
|
|---|---|
Return on Assets (Normalized) | −36.48% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
BOLD
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mytvbqbh | Kbgy | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pfjymygnm | Ybwjly | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mgzqrfcmp | Wwmtwf | $98.1 Bil | |
MRNA
| Moderna Inc | Klbhbkzbf | Kczlh | $39.1 Bil | |
ARGX
| argenx SE ADR | Gzbjnwjn | Mmys | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Fsqrhqyq | Xrrr | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qlkfrfyb | Tvhhdl | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Stckpbyp | Lfxnzj | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zkhxlgmzr | Svkyqd | $12.5 Bil | |
INCY
| Incyte Corp | Kmmvlbwy | Dylxgx | $11.9 Bil |